Chardan Capital Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $22
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
Chardan Capital analyst Geulah Livshits initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $22.
Chardan Capital analyst Geulah Livshits initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $22.